Lessons from Practice
A full course of HBV vaccine results in protective levels of neutralising antibody to HBV (anti-HBs, у 10 IU/L) in over 90% of adults. 1 Rare cases of "vaccine breakthrough" infection in actively vaccinated individuals, mainly involving "vaccine escape mutants", have been documented. [2] [3] [4] The infecting strain usually carries mutations in the major antigenic region of HBsAg that result in suboptimal detection by HBsAg tests and, on occasion, incomplete neutralisation by vaccine-induced antibodies. 4 Unless symptomatic, or tested for some other reason, these infections invariably go unrecognised. However, a sensitive HBV DNA assay near the onset of infection may result in an atypical test pattern suggestive of acute infection (ie, HBV DNA detected; HBsAg not detected; anti-HBc not detected; anti-HBs detected [caused by prior vaccination]). With increasing use of HBV DNA assays for blood donor screening, these cases are now more likely to be detected and referred for clinical management. 5, 6 Nucleic acid amplification testing for HBV DNA reduces the window period for detecting HBV compared with serological screening, which will not identify donors with HBV infection before the appearance of HBsAg. In July 2010, to improve the safety of blood products, the Australian Red Cross Blood Service augmented its HBsAg screening protocol (PRISM HBsAg assay, Abbott Diagnostics) by implementing nucleic acid amplification testing of all donations (ULTRIO HIV-1/HCV/HBV assay, Novartis Diagnostics). The two cases of apparent vaccine breakthrough infection that we report were recognised subsequently; both blood donors had a history of HBV vaccination and were found to be HBV nucleic acid reactive with anti-HBs at protective levels (у 10 IU/L), and all other serological markers for HBV were initially nonreactive.
To our knowledge, these cases are novel in Australia. Similar occurrences have been reported in paediatric transfusion recipients in Taiwan 7 and in blood donors in the United States 5, 6 and Thailand. 8 They are distinct from chronic (ie, anti-HBc positive) occult HBV infection, which is characterised by undetectable HBsAg and very low levels of HBV DNA. 9 Given the complete absence of detectable HBsAg in one donor, and that neither donor identified a past history of hepatitis (a trigger for anti-HBc testing), at least one case, and probably both cases, would have gone unrecognised before the implementation of universal HBV DNA testing. Consistent with previously published cases with comprehensive follow-up, 5, 6 the immediate and longterm clinical significance of these two cases of infection appears to be inconsequential. Neither donor reported any clinical symptoms of hepatitis, and both remained well during the period of follow-up. A slight rise in alanine aminotransferase level was apparent in Case 2, although all other liver function test results remained normal. Both donors had a transient viraemia followed by an increase in anti-HBs and seroconversion to anti-HBc, with detectable IgM anti-HBc confirming recent infection. Follow-up test results showed subsequent appearance of HBsAg 1 month later, followed by HBeAg (HBV e antigen). Viral load peaked at 160 000 IU/mL (index + 52 days). Three months after the index donation, both HBsAg and HBV DNA were undetectable; however, IgM anti-HBc, total anti-HBc and anti-HBe (antibodies to HBeAg) were present, confirming recent infection. Consistent with Case 1, a marked increase in the anti-HBs concentration (to 894 IU/L) was observed subsequent to DNA disappearance. The donor remained asymptomatic throughout, but a slightly raised level of alanine aminotransferase (73 U/L; reference interval, < 40 U/L) was noted; other liver function test results were normal.
◆
The viraemic period may mean that such individuals represent a temporary risk to others (for example, sexual partners and recipients of their blood). From the limited published data, it appears that the risk of transfusion transmission is substantially reduced compared with conventional window-period HBV infection. A number of studies confirm the infectivity of blood with detectable HBV DNA. Two cases of transmission where anti-HBs exceeds 10 IU/L have been reported, but none with levels above 30 IU/L. 10, 11 The underlying mechanism of vaccine breakthrough in our donors is uncertain. Their genotypes (E and C) may be significant; one study noted that non-A2 genotypes were significantly more prevalent among five vaccine breakthrough cases, 5 and the authors speculated that the HBV vaccine (with A2 parent strain) provides suboptimal protection against infection with non-A2 genotypes but sufficient protection to prevent clinical disease.
Since both donors had detectable DNA at their index donations and were therefore identified by our improved routine screening strategy, their donations posed no risk to the safety of the blood supply. Case 2 required a risk assessment of three prior donations, the most recent of which was 6 months before the positive index donation. • This may be relevant to clinicians when investigating a recent risk event, for example, high-risk sexual contact or a needle-stick injury, including vaccinated individuals with an anti-HBs level у 10 IU/L.
• The immediate and longer-term clinical significance for the two donors appears to be inconsequential, and, since both cases were detected by routine HBV DNA screening these blood donations posed no safety risk.
• While the donors may pose a temporary risk to close personal contacts, the risk level is substantially lower when compared with classical acute infections. 
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